search
Back to results

Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women

Primary Purpose

Tobacco Use Disorder

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Bupropion SR
placebo
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tobacco Use Disorder focused on measuring Tobacco use cessation, Bupropion, Zyban, Puerperium

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Postpartum women who: Smoked >1 cigarette in last month of pregnancy Deliver a baby at Brigham and Women's Hospital in Boston, MA Do not breastfeed or plan to breastfeed. Want to attempt to stop smoking Exclusion Criteria: Age <18 years; Current use of bupropion or antidepressant; Current major depression or other severe psychiatric illness (e.g., schizophrenia, mania); Contraindication to use of bupropion; Illegal substance use in past 6 months; >1 drink/day of alcohol during pregnancy; Newborn with major congenital anomaly or <25 weeks' gestation; Inability to speak or read English; No telephone.

Sites / Locations

  • Brigham and Women's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

Bupropion SR

Arm Description

Sugar pill

Outcomes

Primary Outcome Measures

Proportion of women who are eligible for the study
Proportion of eligible women who enroll in the study
Proportion of enrolled women who complete the study

Secondary Outcome Measures

Cotinine-verified 7-day tobacco abstinence at 2 weeks
Cotinine-verified 7-day tobacco abstinence at 8 weeks
Cotinine-verified 7-day tobacco abstinence at 12 weeks
Symptoms of depression at 2, 8, and 12 weeks postpartum
Symptoms of anxiety at 2, 8, and 12 weeks postpartum
Adherence to study drug at 2 and 8 weeks postpartum
Rate of adverse effects at 2 and 8 weeks postpartum

Full Information

First Posted
July 5, 2005
Last Updated
April 28, 2011
Sponsor
Massachusetts General Hospital
Collaborators
Robert Wood Johnson Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00119210
Brief Title
Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women
Official Title
Bupropion for Smoking Cessation in Postpartum Women
Study Type
Interventional

2. Study Status

Record Verification Date
April 2011
Overall Recruitment Status
Terminated
Why Stopped
We were unable to recruit sufficient numbers of patients and decided that the study protocol was not feasible to implement
Study Start Date
March 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Massachusetts General Hospital
Collaborators
Robert Wood Johnson Foundation

4. Oversight

5. Study Description

Brief Summary
The purpose of this small preliminary study is to determine whether it is feasible to recruit women smokers who have just delivered a baby and are not breastfeeding into a study that would test whether starting bupropion, a smoking cessation medication, after a baby's birth helps a postpartum woman to stop smoking.
Detailed Description
Purpose: A pilot randomized double-blind placebo-controlled trial is testing the feasibility of conducting a full-scale trial of the efficacy of bupropion SR vs. placebo in non-breastfeeding postpartum women who smoked >1 cigarette in the last month of pregnancy and want to stop smoking. The study will estimate achievable enrollment and retention rates; estimate the effect size of the drug on tobacco abstinence; assess the tolerability of bupropion in postpartum women; and allow refinement of recruitment, retention, intervention, and assessment protocols. Research Design: Pilot double-blind placebo-controlled randomized clinical trial. Study Population: 40 postpartum women aged 18 years or older who smoked > 1 cigarette in the last month of pregnancy, want to stop smoking, and are not breastfeeding. Subjects will be recruited postpartum while hospitalized after delivery. Intervention: Bupropion SR (or matching placebo) for 8 weeks, starting immediately post-delivery. The dose is 150 mg qd for one week then 150 mg bid for 7 weeks. All subjects will receive behavioral counseling delivered face-to-face during the post-delivery hospitalization and by telephone 4 times over 8 weeks. Outcome Measures: (assessed at 2, 4, 8, and 12 weeks postpartum): Study eligibility, recruitment, and retention rates (primary outcome). Tobacco abstinence (7-day point prevalence nonsmoking by self-report and confirmed by saliva cotinine at 2 weeks, 8 weeks (end of drug treatment), and 12 weeks postpartum. Postpartum weight loss and symptoms of depression and anxiety. Tolerability of postpartum bupropion, assessed by medication adherence and adverse effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tobacco Use Disorder
Keywords
Tobacco use cessation, Bupropion, Zyban, Puerperium

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Sugar pill
Arm Title
Bupropion SR
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Bupropion SR
Intervention Type
Other
Intervention Name(s)
placebo
Primary Outcome Measure Information:
Title
Proportion of women who are eligible for the study
Title
Proportion of eligible women who enroll in the study
Title
Proportion of enrolled women who complete the study
Secondary Outcome Measure Information:
Title
Cotinine-verified 7-day tobacco abstinence at 2 weeks
Title
Cotinine-verified 7-day tobacco abstinence at 8 weeks
Title
Cotinine-verified 7-day tobacco abstinence at 12 weeks
Title
Symptoms of depression at 2, 8, and 12 weeks postpartum
Title
Symptoms of anxiety at 2, 8, and 12 weeks postpartum
Title
Adherence to study drug at 2 and 8 weeks postpartum
Title
Rate of adverse effects at 2 and 8 weeks postpartum

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Postpartum women who: Smoked >1 cigarette in last month of pregnancy Deliver a baby at Brigham and Women's Hospital in Boston, MA Do not breastfeed or plan to breastfeed. Want to attempt to stop smoking Exclusion Criteria: Age <18 years; Current use of bupropion or antidepressant; Current major depression or other severe psychiatric illness (e.g., schizophrenia, mania); Contraindication to use of bupropion; Illegal substance use in past 6 months; >1 drink/day of alcohol during pregnancy; Newborn with major congenital anomaly or <25 weeks' gestation; Inability to speak or read English; No telephone.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nancy A Rigotti, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women

We'll reach out to this number within 24 hrs